Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection

Biomedical Chromatography

Volumn 18, Issue 9, 2004, Pages 667-672

  Tenmizu, Daisuke ^a   Fukunaga, Yasuhisa ^a   Noguchi, Kiyoshi ^a   Kamimura, Hidetaka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Fluorescence; Simultaneous determination; YM 64227

Indexed keywords

BIOMOLECULES; CHROMATOGRAPHIC ANALYSIS; ESTERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES;

ANALYTES; DOG PLASMA; FLUORESCENCE DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTIONS; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; PHOSPHODIESTERASES; PLASMA SAMPLES; REVERSED-PHASE HIGH PERFORMANCE; SIMULTANEOUS DETERMINATIONS; YM-64227;

FLUORESCENCE;

4 CYCLOHEXYL 1 ETHYL 7 METHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; ACETIC ACID; ACETONITRILE; DRUG METABOLITE; PHENYL GROUP; PHOSPHODIESTERASE IV INHIBITOR; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG; YM 64227;

ACCURACY; ALKALINITY; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; EXCITATION; FLOW RATE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; NONHUMAN; PROCESS DEVELOPMENT; PROCESS MONITORING; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; STANDARD; VALIDATION PROCESS;

CANIS FAMILIARIS;

EID: 9144221103     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.371     Document Type: Article

References (20)

1. Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K and Yamada T. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. Journal of Pharmacology and Experimental Therapy 2000; 295: 255-260.
2. Aoki M, Yamamoto S, Kobayashi M, Ohga K, Kanoh H, Miyata K, Honda K and Yamada T. Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. Journal of Pharmacology and Experimental Therapy 2001; 297: 165-173.
3. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiology Review 1995; 75 725-748.
4. Dent G, Giembycz MA, Rabe KF and Barnes PJ. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. British Journal of Pharmacology 1991; 103: 1339-1346.
5. Germain N, Bertin B, Legendre A, Martin B, Lagente V, Payne A and Boichot E. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs. European Respiratory Journal 1998; 12: 1334-1339.
6. Goncalves de Moraes VL, Singer M, Vargaffig BB and Chignard M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. British Journal of Pharmacology 1998; 123: 631-636.
7. Harris AL, Connell MJ, Ferguson EW, Wallace AM, Gordon RJ, Pagani ED and Silver PJ. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. Journal of Pharmacology and Experimental Therapy 1989; 251: 199-206.
8. Heaslip RJ, Lombardo LJ, Golankiewicz JM, Ilsemann BA, Evans DY, Sickels BD, Mudrick JK, Bagli J and Weichman BM. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. Journal of Pharmacology and Experimental Therapy 1994; 268: 888-896.
9. Holbrook M, Gozzard N, James T, Higgs G and Hughes B. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. British Journal of Pharmacology 1996; 118: 1192-1200.
10. Howell RE, Jenkins LP and Howell DE. Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. Journal of Pharmacology and Experimental Therapy 1995; 275: 703-709.
11. Iwata M, Takayama K, Hisamichi H, Kubota H, Kawano N, Aoki M and Isomura Y. Synthetic studies on selective type IV phosphodiesterase (PDEIV) inhibitors. III. 216th American Chemical Society National Meeting 1998; Book of abstracts part 2 medicinal chemistry division 47.
12. Moriuchi H, Nakahara T, Maruko T, Sakamoto K and Ishii K. Relaxant effect of YM976, a novel phosphodiesterase 4 inhibitor, on bovine tracheal smooth muscle. European Journal of Pharmacology 2003; 470: 57-64.
13. Peachell PT, Undem BJ, Schleimer RP, MacGlashan DW Jr, Lichtenstein LM, Cieslinski LB and Torphy TJ. Preliminary identification and role of phosphodiesterase isozymes in human basophils. Journal of Immunology (Baltimore, MD 1950) 1992; 148: 2503-2510.
14. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE and Webber et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. British Journal of Pharmacology 1994; 113:1423-1431.
15. Shahid M, van Amsterdam RG, de Boer J, ten Berge RE, Nicholson CD and Zaagsma J. The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. British Journal of Pharmacology 1991; 104: 471-477.
16. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB and Compton CH. Ariflo TM(SB 207499), a Second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulmonary Pharmacology and Therapeutics 1999; 12: 131-135.
17. Torphy TJ, Burman M, Huang LB and Tucker SS. Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. Journal of Pharmacology and Experimental Therapy 1988; 246: 843-850.
18. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM and Torphy TJ. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. Journal of Pharmacology and Experimental Therapy 1993; 266: 306-313.
19. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW and Torphy TJ. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. Journal of Pharmacology and Experimental Therapy 1994; 270: 250-259.
20. Weston MC, Anderson N and Peachell PT. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. British Journal of Pharmacology 1997; 121: 287-295.